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In a retrospective analysis of 215 patients with carbapenem-resistant
Pseudomonas aeruginosa sepsis, we observed a signiﬁcantly higher risk of mortality
associated with respiratory tract infection (risk ratio [RR], 1.20; 95% conﬁdence interval [CI], 1.04 to 1.39; P ⫽ 0.010) and lower risk with urinary tract infection (RR, 0.80;
95% CI, 0.71 to 0.90; P ⫽ 0.004). Aminoglycoside monotherapy was associated with
increased mortality, even after adjusting for confounders (adjusted RR, 1.72; 95% CI,
1.03 to 2.85; P ⫽ 0.037), consistent across multiple sites of infection.

ABSTRACT
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I

nfections due to carbapenem-resistant Gram-negative organisms represent an
emerging threat to public health worldwide (1). The majority of carbapenem-resistant
Gram-negative infections are caused by nonfermenters, most commonly, Pseudomonas
aeruginosa (2). Multidrug-resistant P. aeruginosa is classiﬁed as a serious threat according to the most recent U.S. Centers for Disease Control and Prevention report, and 20%
to 30% of clinical isolates are carbapenem resistant (1, 3). Mortality associated with
these infections is high (20% to 50%), making optimal and timely treatment essential
(4, 5). Unfortunately, the treatment of choice for carbapenem-resistant P. aeruginosa
infection remains uncertain, and management is primarily based on pathogen-directed
susceptibility patterns (6, 7).
We conducted a single-center retrospective cohort study at Barnes-Jewish Hospital
(St. Louis, MO, USA), a 1,315-bed tertiary care academic medical center, to evaluate the
comparative effectiveness of antibiotic agents used in the management of sepsis due
to carbapenem-resistant P. aeruginosa infection (2012 to 2015). Inclusion criteria were
age ⱖ18 years, hospital admission, carbapenem-resistant P. aeruginosa isolated from
any site, and sepsis, deﬁned as ⱖ2 systemic inﬂammatory response syndrome (SIRS)
criteria (8). Exclusion criteria were cystic ﬁbrosis (CF), polymicrobial infection, recurrent
infection (only ﬁrst case analyzed), and discharge to home alive without receiving
appropriate targeted antibiotic therapy. Carbapenem resistance was deﬁned as pheApril 2018 Volume 62 Issue 4 e02400-17
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notypic nonsusceptibility to meropenem or imipenem. Clinical data were collected
retrospectively from the electronic medical record. Comorbidities were identiﬁed by
diagnosis codes as recorded by a treating physician. The primary outcome was all-cause
in-hospital mortality. Baseline characteristics were compared by using the chi-squared
test or Fisher’s exact test for categorical data and Student’s t test or the Mann-Whitney
U test for continuous data. Multivariable log-binomial regression analysis was conducted to determine variables associated with mortality. Susceptibility testing was
performed during routine clinical care using the disk diffusion method according to
Clinical Laboratory and Standards Institute (CLSI) guidelines current at the time of
infection (9). The Washington University in St. Louis institutional review board approved
this study, and a P value of ⬍0.05 was considered statistically signiﬁcant.
A total of 2,736 patients with carbapenem-resistant Gram-negative infections were
screened. Patients were excluded if they had ⬍2 SIRS criteria (n ⫽ 1,700), CF (n ⫽ 91),
recurrent infection (n ⫽ 392), lack of appropriate treatment before discharge alive (n ⫽
64), and infection due to a Gram-negative organism other than P. aeruginosa (n ⫽ 274).
A total of 215 patients with carbapenem-resistant P. aeruginosa sepsis were included in
the ﬁnal analysis. Overall, in-hospital mortality was 21.4% (46/215). Factors associated
with mortality are shown in Table 1. The most common site of infection was the
respiratory tract, which was associated with a greater risk of mortality than other sites
of infection (28.8% [30/104] versus 14.4% [16/111]; risk ratio [RR], 1.20; 95% conﬁdence
interval [CI], 1.04 to 1.39; P ⫽ 0.010). The reason for this observation is unclear but may
be related to difﬁculty in organism identiﬁcation, leading to delayed appropriate
therapy or suboptimal antibiotic penetration into the lung parenchyma. Conversely,
urinary tract infections were associated with a lower risk of mortality than other sites of
infection (6.5% [3/46] versus 25.4% [n ⫽ 43/169]; RR, 0.80; 95% CI, 0.71 to 0.90; P ⫽
0.004), underscoring the importance of infection site on outcomes among patients with
carbapenem-resistant P. aeruginosa infection.
The most commonly utilized treatment modality was monotherapy with cefepime
(n ⫽ 88). At our institution, cefepime is the treatment of choice for empirical therapy
due to suspected P. aeruginosa infection, and dual Gram-negative coverage is not
routinely utilized because of cefepime susceptibility rates of ⬃90% among non-CF
P. aeruginosa isolates. These susceptibility rates consistently exceed those of meropenem by 5% to 10%, and it is not uncommon to encounter cases of infection due
to carbapenem-resistant P. aeruginosa with retained susceptibility to other antipseudomonal ␤-lactam agents, including cefepime or piperacillin-tazobactam (our
unpublished data). In a recent study at the University of Pittsburgh Medical Center,
68% of carbapenem-resistant P. aeruginosa bloodstream isolates were susceptible
to cefepime, and 57% were susceptible to piperacillin-tazobactam (7). Whether
treatment of infections due to this susceptibility pattern requires use of more-toxic
agents, such as aminoglycosides or polymyxins; more-expensive agents, such as
novel ␤-lactam/␤-lactamase inhibitors; or combinations of multiple active agents
remains unclear (10). In the present study, we did not observe increased mortality
associated with use of cefepime monotherapy (15.9% [14/88] versus 25.2% [32/127];
RR, 0.89; 95% CI, 0.77 to 1.02; P ⫽ 0.102) or piperacillin-tazobactam monotherapy
(17.4% [8/46] versus 22.5% [38/169]; RR, 0.94; 95% CI, 0.80 to 1.10; P ⫽ 0.455)
compared with mortality with all other therapies, suggesting that these agents may
still be of utility in the management of select cases of carbapenem-resistant P.
aeruginosa infection. There was no difference in mortality between patients receiving combination therapy and those receiving monotherapy (27.3% [3/11] versus
21.1% [43/204]; RR, 1.09; 95% CI, 0.75 to 1.57; P ⫽ 0.705), albeit this was a limited
sample. Previous literature suggested a beneﬁt of deﬁnitive treatment with combination therapy in carbapenem-resistant Enterobacteriaceae infection, but the data
do not appear to support increased effectiveness against multidrug-resistant P.
aeruginosa, consistent with our ﬁndings (10).
Aminoglycoside monotherapy was associated with an increased risk of mortality
compared to other monotherapies (38.5% [15/39] versus 17.0% [28/165]; RR, 1.35; 95%
aac.asm.org 2
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TABLE 1 Characteristics associated with all-cause in-hospital mortality among patients
with sepsis due to carbapenem-resistant Pseudomonas aeruginosa
Survivor
(n ⴝ 169)
58 (44–67)
59 (34.9)

Nonsurvivor
(n ⴝ 46)
61 (52–70)
19 (41.3)

P value
0.060
0.424

Yr of infection (n [%])
2012
2013
2014
2015

59 (34.9)
42 (24.9)
28 (16.6)
40 (23.7)

17 (37.0)
7 (15.2)
13 (28.3)
9 (19.6)

0.224
0.797
0.167
0.073
0.556

ICU admission (n [%])
Length of stay (median days [IQR])b
Hospital-acquired infection (n [%])c
Time to appropriate treatment (mean ⫾ SD h)d

86 (50.9)
3 (1–18)
93 (55.0)
16.3 ⫾ 27.6

31 (67.4)
10 (1–29)
33 (71.7)
28.5 ⫾ 77.5

0.046
0.034
0.041
0.302

Antibiotic treatment (n [%])e,f
Aminoglycoside monotherapy
Colistin monotherapy
Cefepime monotherapy
Fluoroquinolone monotherapy
Piperacillin-tazobactam monotherapy
Aztreonam monotherapy
Ceftolozane/tazobactam monotherapy
Combination therapy

24 (14.2)
13 (7.7)
74 (43.8)
10 (5.9)
38 (22.5)
1 (0.6)
1 (0.6)
8 (4.7)

15 (32.6)
1 (2.2)
14 (30.4)
4 (8.7)
8 (17.4)
1 (2.2)
0 (0.0)
3 (6.5)

0.089
0.004
0.311
0.102
0.505
0.455
0.383
⬎0.999
0.705

Infection site (n [%])
Intraabdominal
Respiratory tract
Bloodstream/endovascular
Urinary tract
Skin/soft tissue/osteomyelitis

9 (5.3)
74 (43.8)
17 (10.1)
43 (25.4)
26 (15.4)

3 (6.5)
30 (65.2)
4 (8.7)
3 (6.5)
6 (13.0)

0.081
0.754
0.010
⬎0.999
0.004
0.692

Previous hospitalization (n [%])g
Invasive surgical procedure (n [%])h
Central venous catheter (n [%])h
Urinary catheter (n [%])h
Other invasive device (n [%])h
Mechanical ventilation (n [%])

151 (89.3)
86 (50.9)
133 (78.7)
107 (63.3)
37 (21.9)
105 (62.1)

46 (100)
23 (50.0)
32 (69.6)
32 (69.6)
11 (23.9)
43 (93.5)

0.015
0.915
0.194
0.432
0.771
⬍0.001

Previous antibiotic exposure (n [%])i
Carbapenemi

131 (77.5)
81 (47.9)

42 (91.3)
27 (58.7)

0.036
0.195

Vasopressor requirement (n [%])

70 (41.4)

41 (89.1)

⬍0.001

Immunosuppression (n [%])
Solid organ transplantation
Stem cell transplantation

56 (33.1)
14 (8.3)
18 (10.7)

28 (60.9)
7 (15.2)
5 (10.9)

0.001
0.160
⬎0.999

Acute kidney injury (n [%])j
SIRS criteria (median [IQR])
Charlson comorbidity index (median [IQR])
APACHE II score (median [IQR])

48 (28.4)
3 (2–3)
6 (3–8)
13 (10–17)

13 (28.3)
3 (2–3)
7 (5–11)
15 (12–19)

0.985
0.541
0.007
0.030
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Characteristica (n ⴝ 215)
Age, median (yr [IQR])
Age ⱖ65 yr (n [%])

aIQR,

interquartile range; SD, standard deviation; APACHE II, Acute Physiology and Chronic Health
Evaluation II.
bBefore index culture.
cHospitalized ⬎48 h before index culture without previous evidence of infection.
dTreatment with an agent to which the organism was phenotypically susceptible in vitro.
eMonotherapy deﬁned as receipt of ⬍2 antibiotics to which the organism was susceptible in vitro as
deﬁnitive therapy for ⱖ48 h.
fCombination therapy deﬁned as receipt of ⱖ2 antibiotics to which the organism was susceptible in vitro as
deﬁnitive therapy for ⱖ48 h.
gWithin the preceding 6 months.
hDuring the index hospitalization before index culture.
iWithin the preceding 3 months.
jDetermined by diagnosis code as recorded by a treating physician.
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TABLE 2 Multivariable log-binomial regression model of variables associated with allcause in-hospital mortality among patients with carbapenem-resistant Pseudomonas
aeruginosa sepsis
Variable
Aminoglycoside monotherapya
Vasopressor requirement
Charlson comorbidity index
APACHE II score

P value
0.003
⬍0.001
0.005
0.036

Adjusted RRa
(95% CI)
1.72 (1.03–2.85)
6.85 (2.71–17.35)
1.16 (1.05–1.90)
1.01 (0.98–1.04)

P value
0.037
⬍0.001
0.001
0.394

Downloaded from http://aac.asm.org/ on April 14, 2018 by Washington University in St. Louis

aRR,

Crude RRa
(95% CI)
1.35 (1.04–1.75)
7.68 (3.16–18.69)
1.15 (1.04–1.96)
1.07 (1.01–1.13)

risk ratio. Comparator: all other monotherapies.

CI, 1.04 to 1.75; P ⫽ 0.003). This association persisted after adjusting for confounding
factors in multivariable log-binomial regression (adjusted RR, 1.72; 95% CI, 1.03 to 2.85;
P ⫽ 0.037) (Table 2). Other factors signiﬁcantly associated with an increased risk of
mortality were vasopressor requirement and comorbidity burden (Table 2). In subgroup
analyses by site of infection, aminoglycoside monotherapy was associated with a
signiﬁcantly increased risk of mortality in skin and soft tissue infections/osteomyelitis
(50.0% [3/6] versus 13.0% [3/23]; RR, 1.74; 95% CI, 0.77 to 3.92; P ⫽ 0.047). Aminoglycoside monotherapy was associated with a nonsigniﬁcantly increased risk of mortality
among subgroups of urinary tract (20.0% [1/5] versus 5.0% [2/40]; RR, 1.19; 95% CI, 0.76
to 1.85; P ⫽ 0.205), bloodstream/endovascular (33.3% [1/3] versus 12.5% [2/16]; RR,
1.31; 95% CI, 0.58 to 2.98; P ⫽ 0.364), and intraabdominal (40.0% [10/25] versus 24.7%
[21/85]; RR, 1.25; 95% CI, 0.89 to 1.77; P ⫽ 0.135) infections. Only one patient with
respiratory tract infection was treated with aminoglycoside monotherapy. Although
aminoglycosides distribute well into various tissues, pathophysiological perturbations
in critically ill patients with sepsis leading to increased volume of distribution and
augmented renal clearance may decrease systemic aminoglycoside concentrations and
prevent attainment of pharmacokinetic/pharmacodynamic targets versus isolates displaying MICs near the susceptibility breakpoint, potentially leading to poorer outcomes
(11).
The present study had limitations. This was a retrospective analysis at a single center
and likely lacked sufﬁcient power to detect differences between some antibiotic
regimens. Thus, prospective comparative effectiveness analyses of antibiotic agents for
carbapenem-resistant P. aeruginosa infection are warranted. We included culture results
from all body sites to evaluate the inﬂuence of this variable on patient outcomes;
however, cultures from nonsterile sites may represent colonization rather than true
infection. We attempted to overcome this by limiting analyses to patients with sepsis
only and excluding known colonizers (i.e., CF). Thus, we expect any degree of misclassiﬁcation to be negligible. This study did not feature analyses of antibiotic dosing
strategies, which may have inﬂuenced the results.
In a retrospective analysis of patients with sepsis due to carbapenem-resistant P.
aeruginosa, we evaluated associations between the site of infection and antibiotic
choice on all-cause in-hospital mortality. We found an increased risk of mortality among
patients with respiratory tract infection and a reduced risk of mortality among patients
with urinary tract infection. Aminoglycoside monotherapy was associated with higher
mortality than other treatments, and the magnitude of this effect was consistent across
multiple infection sites. Although additional research is needed, the present study
revealed important relationships between the site of infection, antibiotic selection, and
mortality in patients with carbapenem-resistant P. aeruginosa infection, which should
be considered in future studies.
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